This week in Obstetrics & Gynecology

Nov 19, 2026

Latest episode · 11 min
Editor’s pick

Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial.

In nearly 3000 induced nulliparous women, intrapartum hyoscine butylbromide, sodium bicarbonate, or both did not significantly increase spontaneous vaginal birth compared with placebo, though small benefits cannot be excluded.

BMJ · 2026 · PubMed

This week’s highlights

  1. 01Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial.

    In nearly 3000 induced nulliparous women, intrapartum hyoscine butylbromide, sodium bicarbonate, or both did not significantly increase spontaneous vaginal birth compared with placebo, though small benefits cannot be excluded.

    Michelsen TM et al. · BMJ · 2026

    PMID 43051685

  2. 02Routine Prenatal Ultrasound at 36 Weeks: Impact on Obstetric Clinical Outcomes.

    At one London hospital, a universal 36-week scan with a management pathway was associated with earlier delivery of small babies, better breech detection, and fewer NICU admissions and severe tears.

    Minopoli M et al. · BJOG · 2026

    PMID 43051962

  3. 03A Randomized Trial of Fractionated CO2 Laser With Topical Clobetasol Compared With Fractionated CO2 Laser With Placebo for Treatment of Vulvar Lichen Sclerosus.

    Adding clobetasol to fractionated CO2 laser for vulvar lichen sclerosus did not increase the share of women with a 16-point Skindex-29 improvement, but improved symptom scores and satisfaction.

    Dieter AA et al. · Obstetrics & Gynecology · 2026

    PMID 43044089

  4. 04Five-year risk of cardiovascular events in women with history of pregnancy complicated by fetal growth restriction.

    In a large matched health-records cohort, fetal growth restriction in a first pregnancy was associated with about a third higher five-year risk of heart failure, myocardial infarction or ischaemic stroke.

    Anand K et al. · Ultrasound in Obstetrics & Gynecology · 2026

    PMID 43050674

  5. 05Hypertensive Disorders of Pregnancy and Black-White Racial Disparities in Severe Maternal Morbidity.

    Massachusetts mediation modelling estimated that preventing hypertensive disorders of pregnancy could eliminate about 40 percent of the Black-White disparity in severe maternal morbidity and 58 percent for cardiac complications.

    Smith-Webb RS et al. · Obstetrics & Gynecology · 2026

    PMID 43044078

  6. 06Efficacy and Safety of the Oral Gonadotropin-Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.

    In a 71-woman phase II trial, the oral GnRH antagonist DW4902 suppressed fibroid-related heavy bleeding in at least 73 percent of women, with modest, reversible bone density changes.

    Song JY et al. · BJOG · 2026

    PMID 43052059

  7. 07Chronic Endometritis: Does the Current Evidence Justify Routine Diagnosis and Treatment?

    A critical review finds CD138-based chronic endometritis diagnosis unvalidated and antibiotic treatment without proven reproductive benefit in controlled studies, concluding routine screening and treatment are not justified.

    Pirtea P et al. · Fertility and Sterility · 2026

    PMID 43025833

  8. 08Updated clinical recommendations for cardiovascular risk assessment to facilitate hormone therapy prescribing: incorporating PREVENT risk calculator and the 2026 multisociety lipid guidelines.

    An expert perspective offers a framework for using PREVENT risk categories, coronary calcium scoring and 2026 lipid guidance to inform menopausal hormone therapy initiation and route of administration.

    Shufelt CL et al. · Menopause · 2026

    PMID 43042547

  9. 09The Rising Tide of Cardiovascular Risk in Younger Women.

    An expert commentary argues that rising cardiovascular risk in younger women, partly from adverse pregnancy outcomes, warrants risk assessment and risk-factor treatment alongside growing demand for menopausal hormone therapy.

    Stuenkel CA · Obstetrics & Gynecology · 2026

    PMID 43044091

  10. 10Inflammatory Bowel Disease in Pregnancy.

    A narrative review identifies active inflammatory bowel disease as the strongest predictor of adverse pregnancy outcomes, with most established therapies continued but methotrexate contraindicated in pregnancy.

    Boyd T, Kane S · Obstetrics & Gynecology · 2026

    PMID 43044085

Read the weekly briefing

This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.

This week: two inexpensive labour drugs fail to raise spontaneous birth after induction, a universal 36-week scan shifts term obstetric metrics in London, and adding clobetasol to vulvar laser improves symptoms but misses its primary target.

Welcome to This Week in Obstetrics & Gynecology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.

The BMJ published SAINT, led by Michelsen, a double-blind, placebo-controlled factorial trial run across eleven Norwegian hospitals [1]. Just under three thousand nulliparous women at term undergoing induction of labour were analysed. They were assigned to oral sodium bicarbonate, intravenous hyoscine butylbromide at 20 milligrams per dose, both drugs, or double placebo. Treatment started at the onset of active labour and was repeated every four hours, up to three doses. Spontaneous vaginal birth occurred in about 56 percent of women on double placebo, about 61 percent with either drug alone, and about 57 percent with the combination. No arm produced a statistically significant increase compared with placebo. Hyoscine butylbromide alone came closest, at about four percentage points higher, and that difference was not significant. Serious adverse events were similar between groups, with no treatment-related serious morbidity or deaths. The main limitation is precision: the authors state that small beneficial effects cannot be excluded. Even so, this is a large, well-blinded phase three trial, and the authors conclude that the findings do not support routine intrapartum use of either agent to facilitate spontaneous vaginal birth after induction.

In BJOG, Minopoli and colleagues report a single-centre retrospective study from St George's in London, covering about 37 thousand singleton term pregnancies [2]. From January 2020 the unit replaced targeted scanning with a universal 36-week ultrasound, embedded in a predefined national management pathway. The team used interrupted time-series analysis to compare the periods before and after. The share of small-for-gestational-age infants delivered at 37 to 38 weeks roughly doubled, to about 38 percent. Prenatal detection of breech presentation rose from 78 percent to almost 90 percent. Over the same period, the odds of neonatal intensive care admission were about a quarter lower. The odds of third- and fourth-degree perineal tears were also about a quarter lower. The most important limitation is the design. A before-and-after comparison at one hospital, with the change introduced in 2020, cannot fully separate the effect of the scan from other shifts in practice over the same years. The study adds real-world evidence on how a universal third-trimester scan, tied to a defined pathway, changes obstetric management, and the authors frame it as informing the ongoing debate on routine screening.

Obstetrics & Gynecology published a randomised, double-blind, placebo-controlled trial led by Dieter at nine sites in the United States [3]. Two hundred and one women with vulvar lichen sclerosus who chose fractionated carbon dioxide laser received three laser treatments four to six weeks apart. They were randomised to clobetasol propionate 0.05 percent or a petrolatum placebo, nightly for four weeks and then twice weekly, and 180 women had complete data. About nine in ten participants had already used topical corticosteroids. The primary outcome was an improvement of at least 16 points on the Skindex-29 skin questionnaire. Close to a third of women in each arm reached it, with no significant difference between groups. Clobetasol did produce greater improvement in the symptom domain and the total score, and satisfaction was higher, at about 85 percent against 69 percent. Adverse events were few, with six participants affected in each arm. The main limitation is that the positive findings are secondary outcomes. The trial also has no laser-free arm, so it does not test whether laser itself works. It supports a role for concurrent steroid alongside laser in this group, without establishing one.

Now, four in brief.

In Ultrasound in Obstetrics and Gynecology, Anand and colleagues used the TriNetX health records network to compare nulliparous women with and without coded fetal growth restriction, about 85 thousand per group after propensity matching [4]. Growth restriction in a first pregnancy was associated with about a third higher risk of a composite of heart failure, myocardial infarction and ischaemic stroke within five years postpartum. Each component was raised on its own. The evidence is observational and depends on diagnostic codes. The authors note possible residual confounding by the timing or severity of pre-eclampsia, and possible overlap with small-for-gestational-age coding that could dilute the associations.

A related question about hypertensive disease comes from Obstetrics & Gynecology, where Smith-Webb and colleagues analysed over 1.2 million Black and White birthing people delivering in Massachusetts from 1998 to 2021, using race as a proxy for exposure to racism [5]. Black birthing people had about 64 excess severe maternal morbidity events per ten thousand deliveries. Causal mediation analysis estimated that preventing hypertensive disorders of pregnancy would eliminate about 40 percent of that disparity, and close to 58 percent of the disparity in cardiac complications. These are modelled estimates from observational data. They rest on the assumptions of mediation analysis, and they leave the larger share of the overall disparity unexplained by hypertension.

In BJOG, Song and colleagues report a phase two, double-blind, placebo-controlled trial at twelve Korean hospitals of DW4902, a new oral gonadotropin-releasing hormone antagonist, in 71 premenopausal women with fibroids and heavy menstrual bleeding [6]. Across the 160, 240 and 320 milligram daily doses, at least 73 percent of women reached a near-absent bleeding score in weeks six to twelve, with similar amenorrhoea rates. Fibroid and uterine volumes and pain fell, and haemoglobin rose at the two lower doses. Bone density changes were modest and reversible. With 71 women and twelve weeks of treatment, this is early dose-finding evidence ahead of phase three trials.

Fertility and Sterility carries a critical review by Pirtea and colleagues on chronic endometritis defined by CD138-positive plasma cells [7]. The authors find the diagnostic criteria heterogeneous and unvalidated. They note that these cells vary across the menstrual cycle and are found in fertile women. They also report that antibiotics reduce CD138 positivity, while controlled studies show no effect of treatment on reproductive outcomes. They conclude that routine screening and treatment cannot be justified until biological validity and clinical benefit are established. This is an expert review rather than new data, though its argument draws on large euploid embryo transfer studies.

Three quick signals.

In Menopause, Shufelt and colleagues set out a framework for bringing the PREVENT calculator, which estimates ten- and thirty-year cardiovascular risk, and the 2026 multisociety lipid guideline into hormone therapy decisions, including coronary calcium scoring and route of administration [8]. It is a perspective, with no new outcome data.

On the same theme, Stuenkel argues in Obstetrics & Gynecology that cardiovascular risk is rising in younger women, partly through adverse pregnancy outcomes, just as demand for hormone therapy grows after labelling changes [9]. Her case for treating modifiable risk factors to guideline targets before hormone therapy is expert commentary.

And Boyd and Kane review inflammatory bowel disease in pregnancy, also in Obstetrics & Gynecology [10]. Active disease is the strongest predictor of adverse outcomes, most established therapies can continue, methotrexate is contraindicated, and caesarean delivery is generally favoured for active perianal Crohn disease. This is a narrative review.

Stepping back across this week's papers, the two larger randomised trials both missed their primary endpoints, with any benefit confined to secondary measures or to differences too small to confirm. The one clearly positive trial was a small, short phase two study. The striking associations came instead from retrospective records, coded diagnoses, modelled mediation and before-and-after comparisons, which describe patterns well but cannot show that changing the exposure would change the outcome.

If you only have time for one paper this week, make it SAINT [1]. It is a large, blinded trial of two cheap and widely available intrapartum drugs in one of the commonest scenarios on the labour ward, and it finds no clear evidence that either raises spontaneous birth after induction.

That's your roundup for This Week in Obstetrics & Gynecology. The full transcript and references are available on the episode page. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.

Get Obstetrics & Gynecology every week

By email, Spotify, Apple or any podcast app.

Listen on Apple PodcastsListen on Spotify

Spot something worth flagging?